Answers are grounded in this paper and cite their sources.
Psoriasis is a chronic inflammatory disorder driven by a dysregulated IL-23/Th17 axis which constitutes the target of biological therapies. Obesity comorbidity worsens disease severity and therapeutic response primarily through a bidirectional feedback loop between adipocytes and the immune system mediated by pro-inflammatory adipokines and cytokines. Obesity is characterized by the overproduction of the adipokines visfatin and leptin that activate Th1/Th17 axis, and the downregulation of adiponectin that inhibits Th1/Th17 polarization. Therefore, elucidating the role of adipokines in psoriasis is crucial to understand disease pathogenesis, optimize therapeutic response and identify new therapeutic targets. This study characterized the effects of anti-IL-23 and anti-IL-17 on systemic immune profile of psoriatic patients and their influence on adipocyte-immune crosstalk. Forty psoriatic patients receiving anti-IL-23, anti-IL-17A, or anti IL-17 A and F biologics were evaluated at baseline and week 16. Systemic inflammation was assessed via serum cytokine/adipokine profiling, PBMC gene expression, and cytofluorimetric immunophenotyping. Skin alteration and inflammation was evaluated by immunohistochemistry and real-time analyses. Concurrently, human adipose tissue-derived mesenchymal stem cells from obese donors were differentiated into adipocytes and stimulated with psoriasis-related molecules to evaluate in vitro immunomodulatory responses. All biologics reduced serum visfatin levels, PBMC visfatin gene expression, and circulating TNF-α, alongside a decrease in CD4 + /TNF-α + and CD4 + /IFN-γ + lymphocytes. Cytokine milieu and adipokine balance was also restored in skin context. Patients with suboptimal clinical responses exhibited higher BMIs, elevated baseline IFN-γ, and failure to reduce post-treatment visfatin and TNF-α levels. While all biologics increased regulatory T-cells (Treg) and effector memory Th-cell frequencies, only anti-IL-23 therapy significantly decreased serum IL-17A and Th17 cells. In vitro adipocytes stimulated with visfatin, TNF-α, IFN-γ and IL-17A were triggered to produce IL-23, IL-22, TNF-α, IL-6, CCL20, CXCL8, in addition to visfatin itself, and downregulated the anti-inflammatory adiponectin. Anti-IL-23 and anti-IL-17 therapies modulate circulating immune cells and affect the mutual lymphocytes-adipocytes feedback loop downregulating both inflammatory cytokines involved in psoriasis pathogenesis and Th-activating adipokines. Our explorative findings identified visfatin, TNF-α and IFN-γ as key mediators of this crosstalk, underscoring the potential role of visfatin in sustaining inflammation in obese patients with treatment-resistant psoriasis.
No takes yet. Share an insight, caveat, or question.
Lolli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: